SavedAdd your journal

Journals / Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi / 2022 / Cilt: 12 - Sayı: 3

Natural Compounds Targeting VEGFRs in Kidney Cancer: An In silico Prediction

Iğdır Üniversitesi
Fen-Edebiyat Fakültesi
Biyokimya Bölümü
Iğdır
Türkiye
Fuat KARAKUŞ
Pages
1711–1722
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, Polydatin and Plakortide M gave the closest results to Lenvatinib in the interactions of the compounds with VEGFR-1 and VEGFR-2, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), which target angiogenesis by blocking VEGF signaling, are used in the treatment of many cancers including kidney cancer.
📊
Key Findings & Data:Subsequently, we performed molecular docking studies against VEGFR-1 and VEGFR-2 with Lenvatinib, reported to be the most toxic of TKIs, and the fifteen natural compounds.
💡
Conclusion & Impact:As a result, Polydatin and Plakortide M gave the closest results to Lenvatinib in the interactions of the compounds with VEGFR-1 and VEGFR-2, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:VEGFR-TKIs · natural compounds · kidney cancer

Abstract

Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), which target angiogenesis by blocking VEGF signaling, are used in the treatment of many cancers including kidney cancer. Despite their efficacy in cancer, serious adverse effects such as hypertension and cardiovascular toxicities remain a clinical challenge. Natural non-toxic compounds targeting VEGFRs might be an alternative to VEGFR-TKIs. In the current study, we screened databases and literature which recommend natural compounds for kidney cancer and found approximately five hundred natural compounds. After screening for toxicity and drug-likeliness properties, fifteen of these compounds remained. Subsequently, we performed molecular docking studies against VEGFR-1 and VEGFR-2 with Lenvatinib, reported to be the most toxic of TKIs, and the fifteen natural compounds. As a result, Polydatin and Plakortide M gave the closest results to Lenvatinib in the interactions of the compounds with VEGFR-1 and VEGFR-2, respectively.

🔖

Cite This Article

Üniversitesi, I., Fakültesi, F., Bölümü, B., Iğdır, I., Türkiye, T., KARAKUŞ, F. (2022). Natural Compounds Targeting VEGFRs in Kidney Cancer: An In silico Prediction. Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Cilt: 12 - Sayı: 3, 1711–1722. https://ajindex.com/articles/538465

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. del Sol Jiménez M, Garzón SP, Rodríguez AD, 2003. Plakortides M and N, bioactive polyketide endoperoxides from the Caribbean marine sponge Plakortis halichondrioides. J Nat Prod. 66(5):655-661.
  2. Du QH, Peng C, Zhang H, 2013. Polydatin: a review of pharmacology and pharmacokinetics. Pharmaceutical biology, 51(11):1347–1354.
  3. Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R, 2021. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC Cancer. 21(1):1021. Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M, 2020. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 84:101966.
  4. Gao Y, Dai X, Li Y, Li G, Lin X, Ai C, Cao Y, Li T, Lin B, 2020. Role of Parkin-mediated mitophagy in the protective effect of polydatin in sepsis-induced acute kidney injury. Journal of translational medicine, 18(1):114. Haque I, Subramanian A, Huang CH, Godwin AK, Van Veldhuizen PJ, Banerjee S, Banerjee SK, 2017. The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review. Int J Mol Sci. 19(1):107. Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, Yi C, 2021. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 147(8):2407-2420.
  5. Jeong W, Doroshow JH, Kummar S, 2013. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer. 37(3):110-144.
  6. Ji H, Zhang X, Du Y, Liu H, Li S, Li L, 2012. Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 87(1):50-59.
  7. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I, 2004. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem. 279(34):36148-57.
  8. Kang HG, Lee HK, Cho KB, Park SI, 2021. A Review o